Synthesis and structure-activity relationship studies of pyrazole-based heterocycles as antitumor agents

Archiv der Pharmazie

Volumn 343, Issue 7, 2010, Pages 384-396

  Farag, Ahmad M ^a   Mayhoub, Abdelrahman S ^b   Eldebss, Taha M A ^a   Amr, Abdel Galil E ^c   Ali, Korany A K ^c   Abdel Hafez, Naglaa A ^c   Abdulla, Mohamed M ^d  

^a CAIRO UNIVERSITY   (Egypt)

^b Al Azhar University   (Egypt)

^c NATIONAL RESEARCH CENTRE   (Egypt)

^d Hi Care Pharmaceutical Co   (Egypt)

Author keywords

1,2,4 triazoles; 1,3,4 oxadiazoles; 1,3,4 thiadiazole; 1,5 diphenylpyrazoles; Anti estrogenic activity

Indexed keywords

1 (4 CYANO 1,5 DIPHENYL 1H PYRAZOLE 3 CARBONYL) 4 PHENYLTHIOSEMICARBAZIDE; 1 (4 CYANO 1,5 DIPHENYL 1H PYRAZOLE 3 CARBONYL)THIOSEMICARBAZIDE; 1,5 DIPHENYL 3 (3 METHYLPYRAZOL 5 ONE 1 CARBONYL)PYRAZOLE 1H 4 CARBONITRILE; 1,5 DIPHENYL 3 (3,5 DIMETHYLPYRAZOLE 1 CARBONYL) 1H PYRAZOLE 4 CARBONITRILE; 1,5 DIPHENYL 3 [5 (PHENYLAMINO) 1,3,4 THIADIAZOL 2 YL] 1H PYRAZOLE 4 CARBONITRILE; 3 (4 CYANO 1,5 DIPHENYL 1H PYRAZOLE 3 YL) 6 (4 METHOXYPHENYL)7H 1,2,4 TRIAZOLO[3,4 B] 1,3,4 THIADIAZINE; 3 (4 CYANO 1,5 DIPHENYL 1H PYRAZOLE 3 YL) 6 PHENYL 7H 1,2,4 TRIAZOLO[3,4 B] 1,3,4 THIADIAZINE; 3 (5 HYDRAZINO 4 PHENYL 4H 1,2,4 TRIAZOL 3 YL) 1,5 DIPHENYL 1H PYRAZOLE 4 CARBONITRILE; 3 (5 MERCAPTO 1,3,4 OXADIAZOLE 2 YL) 1,5 DIPHENYL 1H PYRAZOLE 4 CARBONITRILE; 3 (5 MERCAPTO 4 AMINO 4H 1,2,4 TRIAZOL 3 YL) 1,5 DIPHENYL 1H PYRAZOLE 4 CARBONITRILE; 3 (5 MERCAPTO 4 PHENYL 4H 1,2,4 TRIAZOL 3 YL) 1,5 DIPHENYL 1H PYRAZOLE 4 CARBONITRILE; 3 (5 MERCAPTO 4H 1,2,4 TRIAZOL 3 YL) 1,5 DIPHENYL 1H PYRAZOLE 4 CARBONITRILE; 3 [5 (METHYLTHIO) 4 PHENYL 4H 1,2,4 TRIAZOL 3 YL] 1,5 DIPHENYL 1H PYRAZOLE 4 CARBONITRILE; 4 CYANO 1,5 DIPHENYL 1H PYRAZOLE 3 CARBOXYLIC ACID HYDRAZIDE; 4 CYANO 1,5 DIPHENYL 1H PYRAZOLE(3,4 DIPHENYL 3H THIAZOL 2 YLIDENE) 3 CARBOXYLIC ACID HYDRAZIDE; 4 CYANO 1,5 DIPHENYL 1H PYRAZOLE[4 (4 CHLOROPHENYL) 3 PHENYL 3H THIAZOL 2 YLIDENE] 3 CARBOXYLIC ACID HYDRAZID; 4 CYANO 1,5 DIPHENYL 1H PYRAZOLE[4 (4 METHOXYPHENYL) 3 PHENYL 3H THIAZOL 2 YLIDENE] 3 CARBOXYLIC ACID HYDRAZIDE; 4 CYANO 1,5 DIPHENYL 1H PYRAZOLE[4 METHYL 3 PHENYL 3H THIAZOL 2 YLIDENE) 3 CARBOXYLIC ACID HYDRAZIDE; 6 BENZYL 3 (4 CYANO 1,5 DIPHENYL 1H PYRAZOLE 3 YL) 1,2,4 TRIAZOLO[3,4 B] 1,3,4 THIADIAZOLE; 6 PHENYL 3 (4 CYANO 1,5 DIPHENYL 1H PYRAZOLE 3 YL) 1,2,4 TRIAZOLO[3,4 B] 1,3,4 THIADIAZOLE; ANTIESTROGEN; ANTINEOPLASTIC AGENT; ESTRADIOL; LETROZOLE; PYRAZOLE DERIVATIVE; THIOSEMICARBAZIDE DERIVATIVE; UNCLASSIFIED DRUG; HETEROCYCLIC COMPOUND; NITRILE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TRIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFECT; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; LD 50; MALE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION; ANIMAL; DRUG SCREENING; MOUSE; SPRAGUE DAWLEY RAT; SYNTHESIS; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; ESTROGEN RECEPTOR MODULATORS; FEMALE; HETEROCYCLIC COMPOUNDS; HUMANS; LETHAL DOSE 50; MALE; MICE; NITRILES; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP; TRIAZOLES;

EID: 77954619092     PISSN: 03656233     EISSN: 15214184     Source Type: Journal    
DOI: 10.1002/ardp.200900176     Document Type: Article

References (58)

1. G. D. Leonard, S. M. Swain, J. Natl. Cancer Inst. 2004, 96, 906-920.
2. M. T. McDermott, F. D. Hofeldt, G. S. Kidd, South. Med. J. 1990, 83, 1283-1285.
3. I. S. Fentiman, M. Caleffi, K. Brame, M. A. Chaudary, J. L. Hayward, Lancet 1986, 1, 287-288.
4. L. L. Amsterdam, Fertil. Steril. 2005, 84, 300-304.
5. P. Merviel, Gynecol. Obstet. Fertil. 2006, 34, 66-39.
6. R. Homburg, Hum. Reprod. 2005, 20, 2043-2051.
7. P. Alexandersen, B. J. Riis, J. A. Stakkestad, P. D. Delmas, C. Christiansen, J. Clin. Endocrinol. Metab. 2001, 86, 755-760.
8. W. Khovidhunkit, D. M. Shoback, Ann. Intern. Med. 1999, 130, 431-439.
9. D. Clemett, C. M. Spencer, Drugs 2000, 60, 379-411.
10. H. Yanyan, C. Michael, Y. Yate-Ching, C. Shiuan, Biochem. Pharmacol. 2008, 75, 1161-1169.
11. Textbook of Organic Medicinal and Pharmaceutical Chemistry (Eds.: J. N. Delago, W. A. Remers), 10th ed. Lippincott-Raven Publishers, Philadelphia, 1998, p. 745.
12. S. Martino, J. A. Cauley, E. Barrett-Connor, T. J. Powles, et al., J. Natl. Cancer Inst. 2004, 96, 1751-1761.
13. S. R. Cummings, S. Eckert, K. A. Krueger, D. Grady, et al., J.A.M.A. 1999, 281, 2189-2197.
14. P. Neven, I. Vergote, Lancet 1998, 351, 155-157.
15. F. A. Aleem, M. Predanic, Lancet 1995, 346, 1292-1293.
16. S. B. Gusberg, Cancer 1990, 65, 1463-1464.
17. L. R. Wiseman, K. L. Goa, Drugs 1997, 54, 141-160.
18. K. Holli, Oncology (Huntingt), 1998, 12 (Suppl. 5), 23-27.
19. A. M. H. Brodie, Pharmacol. Ther. 1993, 60, 501-515.
20. W. L. Miller, Endocr. Rev. 1988, 9, 295-318.
21. L. R. Wiseman, D. McTavish, Drugs 1993, 45, 66-84.
22. K. Ellington, D. M. Faulds, Drugs 2002, 62, 2483.
23. U. Gruntmanis, G. D. Braunstein, Curr. Opin. Investig. Drugs 2001, 2, 643-649.
24. P. E. Goss, E. P. Winer, I. F. Tannock, L. H. Schwartz, J. Clin. Oncol. 1999, 17, 52-63.
25. C. L. Harper-Wynne, N. P. Sacks, K. Shenton, F. A. MacNeill, et al., J. Clin. Oncol. 2002, 20, 1026-1035.
26. A. U. Buzdar, R. Smith, C. Vogel, P. Bonomi, et al., Cancer 1996, 77, 2503-2513.
27. E. W. Leschek, J. Jones, K. M. Barnes, S. C. Hill, G. B. Cutler Jr., J. Clin. Endocrinol. Metab. 1999, 84, 175-178.
28. D. Simpson, M. P. Curran, C. M. Perry, Drugs 2004, 64, 1213-1230.
29. J. A. Garcia-Velasco, L. Moreno, A. Pacheco, A. Guillén, et al., Fertil. Steril 2005, 84, 82-87.
30. T. Naruse, Y. Nishida, N. Ishiguro, Biomed. Pharmacother. 2007, 61, 338-346.
31. T. C. Dang, A. J. Dannenberg, K. Subbaramaiah, M. N. Dickler, et al., Clin. Cancer Res. 2004, 10, 4062-4067.
32. D. A. Reardon, J. A. Quinn, J. Vredenburgh, J. N. Rich, et al., Cancer 2005, 103, 329-338.
33. F. W. Nugent, W. C. Mertens, S. Graziano, N. Levitan, et al., Lung Cancer 2005, 48, 267-273.
34. G. Gasparini, S. Meo, G. Comella, S. C. Stani, et al., Cancer J. 2005, 11, 209-216.
35. C. X. Pan, P. Loehrer, D. Seitz, P. Helft, et al., Oncology 2005, 69, 63-70.
36. V. Ferrari, F. Valcamonico, V. Amoroso, E. Simoncini, et al., Cancer Chemother. Pharmacol. 2006, 57, 185-190.
37. I. Csiki, J. D. Morrow, A. Sandler, Y. Shyr, Clin. Cancer Res. 2005, 11, 6634-6640.
38. L. W. Chow, C. W. Cheng, J. L. Wong, M. Toi, Biomed. Pharmacother. 2005, 59 (Suppl. 2), S302-305.
39. M. R. Shaaban, T. S. Saleh, A. M. Farag, Heterocycles 2009, 78, 151-159.
40. M. R. Shaaban, T. S. Saleh, A. M. Farag, Heterocycles 2009, 78, 699-706.
41. N. A. Kheder, Y. N. Mabkhot, A. M. Farag, Heterocycles 2009, 78, 937-946.
42. A. M. Farag, N. A. Kheder, Y. N. Mabkhot, Heterocycles 2009, 78, 1787-1798.
43. A. M. Farag, A. S. Mayhoub, S. E. Barakat, A. H. Bayomi, Bioorg. Med. Chem. 2008, 16, 4569-4578.
44. A. M. Farag, A. S. Mayhoub, S. E. Barakat, A. H. Bayomi, Bioorg. Med. Chem. 2008, 16, 881-889.
45. A. S. Girgis, N. Mishriky, A. M. Farag, W. I. El-Eraky, H. Farag, Eur. J. Med. Chem. 2008, 43, 1818-1827.
46. M. R. Shaaban, T. S. Saleh, A. S. Mayhoub, A. Mansour, A. M. Farag, Bioorg. Med. Chem. 2008, 16, 6344-6352.
47. A. M. Farag, Y. M. Elkholy, K. A. Ali, J. Heterocycl. Chem. 2008, 45, 279-283.
48. N. A. Kheder, Y. N. Mabkhot, A. M. Farag, Heterocycles 2008, 75, 2937-2948.
49. N. A. Kheder, Y. N. Mabkhot, A. M. Farag, Heterocycles 2008, 75, 887-897.
50. N. A. Kheder, Y. N. Mabkhot, A. M. Farag, Synth. Comm. 2008, 38, 3170-3182.
51. K. M. Dawood, A. M. Farag, N. A. Khedr, Arkivoc 2008, xv, 166-175.
52. N. A. Kheder, Y. N. Mabkhot, A. M. Farag, Arkivoc 2008, xvii, 107-116.
53. A. S. Shawali, J. Heterocycl. Chem. 1977, 14, 375-381.
54. C. S. Weil, Biometrics 1952, 8, 249-263.
55. C. W. Dunnett, J. Am. Stat. Assoc. 1955, 50, 1096-1121.
56. M. R. Grever, S. A. Schepartz, B. A. Chabner, Sem. Oncol. 1992, 19, 622-638.
57. M. R. Boyd, K. D. Paull, Drug Dev. Res. 1995, 34, 91-109.
58. A. Monks, D. Scudiero, P. Skehan, R. Shoemaker, et al., J. Natl. Cancer Inst. 1991, 83, 757-766.